173 related articles for article (PubMed ID: 8061423)
1. Contrast-enhanced MR imaging of the liver.
Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
[TBL] [Abstract][Full Text] [Related]
2. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of liver contrast agents: impact for clinical use.
Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
[TBL] [Abstract][Full Text] [Related]
4. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
[TBL] [Abstract][Full Text] [Related]
5. Liver-specific MR imaging contrast agents.
Hahn PF; Saini S
Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
[TBL] [Abstract][Full Text] [Related]
7. Safety of approved MR contrast media for intravenous injection.
Runge VM
J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
9. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
Reimer P; Schneider G; Schima W
Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
[TBL] [Abstract][Full Text] [Related]
10. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.
Tang Y; Yamashita Y; Arakawa A; Namimoto T; Mitsuzaki K; Abe Y; Katahira K; Takahashi M
AJR Am J Roentgenol; 1999 Jun; 172(6):1547-54. PubMed ID: 10350287
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gadolinium chelates with manganese-DPDP for liver lesion detection and characterization: preliminary results.
Kettritz U; Schlund JF; Wilbur K; Eisenberg LB; Semelka RC
Magn Reson Imaging; 1996; 14(10):1185-90. PubMed ID: 9065909
[TBL] [Abstract][Full Text] [Related]
12. Combined use of MR contrast agents for evaluating liver disease.
Ward J; Robinson PJ
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
[TBL] [Abstract][Full Text] [Related]
13. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
[TBL] [Abstract][Full Text] [Related]
14. Imaging liver metastases: review and update.
Kanematsu M; Kondo H; Goshima S; Kato H; Tsuge U; Hirose Y; Kim MJ; Moriyama N
Eur J Radiol; 2006 May; 58(2):217-28. PubMed ID: 16406434
[TBL] [Abstract][Full Text] [Related]
15. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.
del Frate C; Bazzocchi M; Mortele KJ; Zuiani C; Londero V; Como G; Zanardi R; Ros PR
Radiology; 2002 Dec; 225(3):766-72. PubMed ID: 12461259
[TBL] [Abstract][Full Text] [Related]
16. [New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)].
Reimer P; Tombach B; Daldrup H; Hesse T; Sander G; Balzer T; Shamsi K; Berns T; Rummeny EJ; Peters PE
Radiologe; 1996 Feb; 36(2):124-33. PubMed ID: 8867429
[TBL] [Abstract][Full Text] [Related]
17. Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions.
Vogl TJ; Hammerstingl R; Schwarz W; Mack MG; Müller PK; Pegios W; Keck H; Eibl-Eibesfeldt A; Hoelzl J; Woessmer B; Bergman C; Felix R
Radiology; 1996 Mar; 198(3):881-7. PubMed ID: 8628887
[TBL] [Abstract][Full Text] [Related]
18. Enhanced liver MR: contrast agents and imaging strategy.
Runge VM; Kirsch JE; Wells JW; Awh MH; Bittner DF; Woolfolk CE
Crit Rev Diagn Imaging; 1993; 34(1-2):1-30. PubMed ID: 8216813
[TBL] [Abstract][Full Text] [Related]
19. [Current status of the clinical development of MR contrast media].
Laniado M; Kopp AF
Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
[TBL] [Abstract][Full Text] [Related]
20. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: initial observations.
Martin DR; Semelka RC; Chung JJ; Balci NC; Wilber K
Magn Reson Imaging; 2000 Oct; 18(8):955-63. PubMed ID: 11121698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
